Australia markets close in 4 hours 11 minutes

Starpharma Holdings Limited (SPL.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
1.3550-0.0300 (-2.17%)
As of 11:40AM AEST. Market open.

Starpharma Holdings Limited

4-6 Southampton Crescent
Abbotsford, VIC 3067
Australia
61 3 8532 2700
http://starpharma.com

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 

Key executives

NameTitlePayExercisedYear born
Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICDCEO, MD & Exec. Director579.15kN/A1963
Mr. Nigel J. Baade B.Com, Grad. Dip., CPACFO & Company Sec.283.08kN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Corporate governance

Starpharma Holdings Limited’s ISS governance QualityScore as of 1 July 2021 is 2. The pillar scores are Audit: 7; Board: 2; Shareholder rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.